Cathepsin D

Detalhes bibliográficos
Autor(a) principal: Gallwitz, Lisa
Data de Publicação: 2022
Outros Autores: Schmidt, Lina, Marques, André R.A., Tholey, Andreas, Cassidy, Liam, Ulku, Irem, Multhaup, Gerhard, Di Spiezio, Alessandro, Saftig, Paul
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/145740
Resumo: Funding Information: This work was supported in part by the Deutsche Forschungsgemeinschaft ( SFB877 , A3 and Z2) and the Canadian Institutes of Health Research – CIHR (to GM). Publisher Copyright: © 2022
id RCAP_acb3d418378cfcdb53b6608623172103
oai_identifier_str oai:run.unl.pt:10362/145740
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Cathepsin DAnalysis of its potential role as an amyloid beta degrading proteaseAlzheimer's diseaseAmyloid betaAmyloid precursor proteinCathepsin-DLysosomeNeuronal ceroid lipofuscinosis 10ProteolysisNeurologySDG 3 - Good Health and Well-beingFunding Information: This work was supported in part by the Deutsche Forschungsgemeinschaft ( SFB877 , A3 and Z2) and the Canadian Institutes of Health Research – CIHR (to GM). Publisher Copyright: © 2022Proteolysis catalyzed by the major lysosomal aspartyl protease cathepsin-D (CTSD) appears to be of pivotal importance for proteostasis within the central nervous system and in neurodegeneration. Neuronal Ceroid Lipofuscinosis (NCL) type 10 is caused by a lack of CTSD leading to a defective autophagic flow and pathological accumulation of proteins. We previously demonstrated a therapeutic-relevant clearance of protein aggregates after dosing a NCL10 mouse model with recombinant human pro-cathepsin-D (proCTSD). Similar results could be achieved in cells and mice accumulating α-synuclein. Prompted by these positive effects and our in vitro findings showing that cathepsin-D can cleave the Alzheimer's Disease (AD)-causing amyloid beta peptides (Aβ), we envisaged that such a treatment with proCTSD could similarly be effective in clearance of potentially toxic Aβ species. We demonstrated that CTSD is able to cleave human Aβ1–42 by using liquid chromatography-mass spectrometry. Intracerebral dosing of proCTSD in a NCL10 (CTSD knockout) mouse model revealed uptake and processing of CTSD to its mature and active form. However, the re-addition of CTSD did not obviously affect intracellular APP processing or the generation of soluble APP and Aβ-species. ProCTSD treated HEK cells in comparison with untreated cells were found to contain comparable levels of soluble and membrane bound APP and Aβ-species. Also, the early intracranial application (P1 and P20) of proCTSD in the 5xFAD mouse model did not change Aβ pathology, plaque number and plaque composition and neuroinflammation, however we observed an increased level of Aβ1–42 in the CSF. Our data confirm proteolytic cleavage of human Aβ1–42 by CTSD but exclude a prominent role of CTSD in APP processing and Aβ degradation in our in vitro and in vivo models.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)iNOVA4Health - pólo NMSRUNGallwitz, LisaSchmidt, LinaMarques, André R.A.Tholey, AndreasCassidy, LiamUlku, IremMulthaup, GerhardDi Spiezio, AlessandroSaftig, Paul2022-11-23T22:26:58Z2022-122022-12-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/145740eng0969-9961PURE: 47854946https://doi.org/10.1016/j.nbd.2022.105919info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:26:21Zoai:run.unl.pt:10362/145740Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:52:14.321599Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Cathepsin D
Analysis of its potential role as an amyloid beta degrading protease
title Cathepsin D
spellingShingle Cathepsin D
Gallwitz, Lisa
Alzheimer's disease
Amyloid beta
Amyloid precursor protein
Cathepsin-D
Lysosome
Neuronal ceroid lipofuscinosis 10
Proteolysis
Neurology
SDG 3 - Good Health and Well-being
title_short Cathepsin D
title_full Cathepsin D
title_fullStr Cathepsin D
title_full_unstemmed Cathepsin D
title_sort Cathepsin D
author Gallwitz, Lisa
author_facet Gallwitz, Lisa
Schmidt, Lina
Marques, André R.A.
Tholey, Andreas
Cassidy, Liam
Ulku, Irem
Multhaup, Gerhard
Di Spiezio, Alessandro
Saftig, Paul
author_role author
author2 Schmidt, Lina
Marques, André R.A.
Tholey, Andreas
Cassidy, Liam
Ulku, Irem
Multhaup, Gerhard
Di Spiezio, Alessandro
Saftig, Paul
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
iNOVA4Health - pólo NMS
RUN
dc.contributor.author.fl_str_mv Gallwitz, Lisa
Schmidt, Lina
Marques, André R.A.
Tholey, Andreas
Cassidy, Liam
Ulku, Irem
Multhaup, Gerhard
Di Spiezio, Alessandro
Saftig, Paul
dc.subject.por.fl_str_mv Alzheimer's disease
Amyloid beta
Amyloid precursor protein
Cathepsin-D
Lysosome
Neuronal ceroid lipofuscinosis 10
Proteolysis
Neurology
SDG 3 - Good Health and Well-being
topic Alzheimer's disease
Amyloid beta
Amyloid precursor protein
Cathepsin-D
Lysosome
Neuronal ceroid lipofuscinosis 10
Proteolysis
Neurology
SDG 3 - Good Health and Well-being
description Funding Information: This work was supported in part by the Deutsche Forschungsgemeinschaft ( SFB877 , A3 and Z2) and the Canadian Institutes of Health Research – CIHR (to GM). Publisher Copyright: © 2022
publishDate 2022
dc.date.none.fl_str_mv 2022-11-23T22:26:58Z
2022-12
2022-12-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/145740
url http://hdl.handle.net/10362/145740
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0969-9961
PURE: 47854946
https://doi.org/10.1016/j.nbd.2022.105919
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138114336194560